Small Molecules

09 Jul 2021 Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD
09 Jul 2021 Surrozen Presents New Data Demonstrating Superior Activity of SZN-1326 in Preclinical Inflammatory Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organisation (ECCO)
09 Jul 2021 Muna Therapeutics Launches with US$ 73M Series A to Advance Novel Small Molecule Therapeutics for Neurodegenerative Diseases
09 Jul 2021 Bacainn Therapeutics Presents at ECCO ‘21 Results from Phase 1 Study that Shows BT051, an Oral, Locally-Acting Inhibitor of Neutrophil Trafficking and Activity, Is Safe and Well-Tolerated in Healthy Adults
07 Jul 2021 Pathios Therapeutics Presents Preclinical In Vivo Proof of Concept Data for small molecule GPR65 inhibitor in human PDX cancer model
07 Jul 2021 Eisbach Bio receives EUR 8 million government grant to progress COVID-19 antiviral through Phase I/II clinical development
07 Jul 2021 UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
06 Jul 2021 Bionomics Initiates Phase 2b ATTUNE Study of BNC210 in PTSD
06 Jul 2021 Almirall and MC2 Therapeutics announce completion of decentralized procedure in Europe for the topical treatment of mild to moderate psoriasis vulgaris in adults
06 Jul 2021 HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China
02 Jul 2021 Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens
02 Jul 2021 Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
02 Jul 2021 LG Chem Announces Topline Results of LC350189 From the Phase 2 Study (CLUE Study) Promising to Be a New Treatment Alternative With Improved Efficacy and Safety Profiles for Chronic Gout Patients
02 Jul 2021 Ildong Pharmaceutical starts Phase 1 study of new diabetes therapy in Germany
02 Jul 2021 Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis
01 Jul 2021 Deciphera Announces First Patient Treated in Phase 1 Study of DCC-3116 in Patients with Advanced or Metastatic Tumors with a Mutant RAS or RAF Gene
01 Jul 2021 Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
01 Jul 2021 Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
01 Jul 2021 Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
01 Jul 2021 Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease
01 Jul 2021 Saniona Initiates Phase 1 Clinical Trial of SAN711
01 Jul 2021 NMD Pharma Doses the First Myasthenia Gravis Patient in a Combined Phase I/IIa Clinical Trial of NMD670
01 Jul 2021 Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis
01 Jul 2021 Cerevel Therapeutics Announces Positive Topline Results for CVL-231 in Phase 1b Clinical Trial in Patients with Schizophrenia
29 Jun 2021 Venatorx Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of VNRX-9945 for the Treatment of Chronic Hepatitis B Virus Infection

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up